USE OF MEMANTINE TO TREAT AUTISM AND ASSOCIATED DISORDERS
Autism spectrum disorder (ASD) is a collection of development disorders of unknown etiology characterized by difficulties in social interaction, verbal and nonverbal communication and repetitive behaviors. In addition to social deficits, ASD can also result in intellectual delays, irritability, problems with motor coordination, …
NOVEL THERAPY TO REDUCE SUICIDAL IDEATION ASSOCIATED WITH SSRI USE
Major Depressive Disorder (depression) is a mental disorder with symptoms including low mood, low self-esteem and loss of pleasure. Approximately 14.8 million patients in the US are affected by depression. Selective Serotonin Reuptake Inhibitors (SSRIs) are commonly used in patients to treat depression, as …
Technology Transfer: Commercialization and Innovation Infographic
by AvalancheInfographics. Explore more visuals like this one on the web’s largest information design community – Visually. …
Intranasal Ketamine Confers Rapid Antidepressant Effect in Depression
April 8, 2014 – A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect –within 24 hours—and was well tolerated in patients with treatment-resistant major …
Harrington Scholar-Innovator Grant Program
The Harrington Scholar-Innovator Award recognizes physician-scientists throughout the U.S. whose research has the potential to change standard of care. The Award provides clinical research funding as well as non-financial support to selected investigators and their institutions to help bridge the gap between …
Erik Lium, PhD, Named Vice President of Mount Sinai Innovation Partners
March 31, 2014 – Erik Lium, PhD, a 16-year veteran with an extensive background in the academic, technology and medical sectors, has been named Vice President and Executive Director of Mount Sinai Innovation Partners, which facilitates the real-world application and commercialization of Mount Sinai …
A NOVEL METHOD TO TREAT ALZHEIMER’S DISEASE AND TUMOR METASTASIS
Alzheimer’s disease (AD) is the most common age-associated dementia. It is a progressive neurodegenerative disorder that correlates with the accumulation of abnormally aggregated amyloid beta (Ab) in the brain. Current therapeutic options do not treat the underlying disease and have several side …
NOVEL METHOD TO SPECIFICALLY INHIBIT CATHEPSIN K COLLAGENOLYTIC ACTIVITY
Bone homeostasis is a complex process and requires a balance between bone formation and resorption. Cathepsin K is a collagenase which is highly expressed in bone resorbing cells and its deficiency leads to pycnodysostosis, a rare disease characterized by a decrease in …
DNA LOCK™: A NOVEL AND SECURE DNA-BASED AUTHENTICATION METHOD
Seized, counterfeit goods in the United States in 2012 were estimated to be worth over $1.30 billion. Current marking techniques can be recovered, copied and illegally used to mark counterfeited goods. To control this increasing problem, reliable counterfeit-resistant techniques are required. Scientists …
Harlem Biospace – Biotech Venture Summer Associate
Harlem Biospace(Hb) is a biotech incubator for New York City offering affordable shared wet-lab space for early-stage biotech companies. We have built a centrally located lab outfitted with modern biotech equipment, host unique classes and events, and provide business support – creating …